Seres Therapeutics, Inc. Earnings Per Share (Basic)
Seres Therapeutics, Inc. (MCRB) reported Earnings Per Share (Basic) of $0.47 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-05
- Seres Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-06-30 was $0.47.
- Seres Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$2.08, a 155.32% decline year-over-year.
- Seres Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$1.66.
- Seres Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-09-30 was $0.94, a 91.92% decline year-over-year.
- Seres Therapeutics, Inc. earnings per share, basic for fiscal 2025 was $0.64.
- Seres Therapeutics, Inc. earnings per share, basic for fiscal 2024 was $0.00.
- Seres Therapeutics, Inc. earnings per share, basic for fiscal 2023 was -$17.77.
- Seres Therapeutics, Inc. earnings per share, basic for fiscal 2022 was -$2.31.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.47 10-Q · filed 2026-08-05 | -$1.59 10-Q · filed 2026-08-05 | -$3.23 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$2.41 derived: net income ÷ weighted average shares · filed 2026-08-05 | ||||
| 2026-03-31 | -$2.08 10-Q · filed 2026-05-05 | -$3.75 derived: net income ÷ weighted average shares · filed 2026-05-05 | -$2.94 derived: net income ÷ weighted average shares · filed 2026-05-05 | -$5.17 derived: net income ÷ weighted average shares · filed 2026-08-05 | ||||
| 2025-12-31 | -$1.66 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$0.79 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$3.03 derived: net income ÷ weighted average shares · filed 2026-08-05 | $0.64 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | $0.94 10-Q · filed 2025-11-05 | -$1.33 derived: net income ÷ weighted average shares · filed 2026-08-05 | $2.41 10-Q · filed 2025-11-05 | $0.62 derived: net income ÷ weighted average shares · filed 2026-08-05 | ||||
| 2025-06-30 | -$2.27 10-Q · filed 2026-08-05 | $1.47 10-Q · filed 2026-08-05 | -$0.32 derived: net income ÷ weighted average shares · filed 2026-08-05 | $10.22 derived: net income ÷ weighted average shares · filed 2026-08-05 | ||||
| 2025-03-31 | $3.76 10-Q · filed 2026-05-05 | $1.97 derived: net income ÷ weighted average shares · filed 2026-05-05 | $12.75 derived: net income ÷ weighted average shares · filed 2026-05-05 | $8.99 derived: net income ÷ weighted average shares · filed 2026-05-05 | ||||
| 2024-12-31 | -$1.83 derived: net income ÷ weighted average shares · filed 2026-03-12 | $9.03 derived: net income ÷ weighted average shares · filed 2026-03-12 | $5.08 derived: net income ÷ weighted average shares · filed 2026-03-12 | $0.00 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | $11.63 10-Q · filed 2025-11-05 | $0.58 10-Q · filed 2024-11-13 | $7.35 derived: net income ÷ weighted average shares · filed 2025-11-05 | $2.10 10-Q · filed 2025-11-05 | $0.11 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | -$4.34 10-Q · filed 2025-08-06 | -$0.22 10-Q · filed 2024-08-13 | -$9.81 10-Q · filed 2025-08-06 | -$0.49 10-Q · filed 2024-08-13 | ||||
| 2024-03-31 | -$5.49 10-Q · filed 2025-05-07 | -$0.27 10-Q · filed 2024-05-08 | ||||||
| 2023-12-31 | -$17.77 10-K · filed 2026-03-12 | -$0.89 10-K · filed 2024-03-05 | ||||||
| 2023-09-30 | -$0.37 10-Q · filed 2024-11-13 | -$0.57 10-Q · filed 2024-11-13 | ||||||
| 2023-06-30 | $0.36 10-Q · filed 2024-08-13 | -$0.19 10-Q · filed 2024-08-13 | -$0.74 derived: net income ÷ weighted average shares · filed 2025-03-13 | -$1.22 derived: net income ÷ weighted average shares · filed 2025-03-13 | ||||
| 2023-03-31 | -$0.57 10-Q · filed 2024-05-08 | -$1.12 derived: net income ÷ weighted average shares · filed 2025-03-13 | -$1.61 derived: net income ÷ weighted average shares · filed 2025-03-13 | -$2.27 derived: net income ÷ weighted average shares · filed 2025-03-13 | ||||
| 2022-12-31 | -$0.55 derived: net income ÷ weighted average shares · filed 2025-03-13 | -$1.04 derived: net income ÷ weighted average shares · filed 2025-03-13 | -$1.71 derived: net income ÷ weighted average shares · filed 2025-03-13 | -$2.31 10-K · filed 2025-03-13 | ||||
| 2022-09-30 | -$0.49 10-Q · filed 2023-11-02 | -$1.16 derived: net income ÷ weighted average shares · filed 2023-11-02 | -$1.77 10-Q · filed 2023-11-02 | -$2.32 derived: net income ÷ weighted average shares · filed 2024-03-05 | ||||
| 2022-06-30 | -$0.70 10-Q · filed 2023-08-08 | -$1.32 10-Q · filed 2023-08-08 | -$1.86 derived: net income ÷ weighted average shares · filed 2024-03-05 | -$1.12 derived: net income ÷ weighted average shares · filed 2024-03-05 | ||||
| 2022-03-31 | -$0.61 10-Q · filed 2023-05-09 | -$1.16 derived: net income ÷ weighted average shares · filed 2024-03-05 | -$0.42 derived: net income ÷ weighted average shares · filed 2024-03-05 | |||||
| 2021-12-31 | -$0.54 derived: net income ÷ weighted average shares · filed 2024-03-05 | $0.20 derived: net income ÷ weighted average shares · filed 2024-03-05 | -$0.72 10-K · filed 2024-03-05 | |||||
| 2021-09-30 | $0.74 10-Q · filed 2022-11-02 | -$0.17 10-Q · filed 2022-11-02 | ||||||
| 2021-06-30 | -$0.53 10-Q · filed 2022-08-03 | -$0.91 10-Q · filed 2022-08-03 | ||||||
| 2021-03-31 | -$0.39 10-Q · filed 2022-05-04 | -$0.59 derived: net income ÷ weighted average shares · filed 2023-03-07 | -$0.95 derived: net income ÷ weighted average shares · filed 2023-03-07 | |||||
| 2020-12-31 | -$0.20 derived: net income ÷ weighted average shares · filed 2023-03-07 | -$0.55 derived: net income ÷ weighted average shares · filed 2023-03-07 | -$1.12 10-K · filed 2023-03-07 | |||||
| 2020-09-30 | -$0.36 10-Q · filed 2021-11-10 | -$0.93 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |